迈威生物 (688062)

Mabwell (Shanghai) Bioscience Co., Ltd.

KSH

Tags

SSE 580 IndexSpecial Purpose LoansLoss-Making StocksInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareBuyback PlansFund Reduction PositionsBiological ProductsPrivate Equity Heavy PositionsSTAR Market Biotechnology IndexTechnology Growth LayerMargin Trading and Securities LendingHigh Price-to-Book Ratio医药生物Chemical Pharmaceuticals

K-Line Chart

No K-line data available

Company NameMabwell (Shanghai) Bioscience Co., Ltd.
Listing Date2022-01-18
Issue Price34.8RMB
Registered Capital3996010k RMB
Legal RepresentativeLiu Datao
Registered AddressRoom 105, Building 2, No. 230 Cailun Road, China (Shanghai) Pilot Free Trade Zone
IndustryChemical Pharmaceuticals
Main BusinessResearch, production, and sales of therapeutic biological products
Company ProfileMabwell (Shanghai) Bioscience Co., Ltd. is an innovative biopharmaceutical enterprise. Its main business is the research, production, and sales of therapeutic biological products, with antibody drugs being its primary products. The issuer adheres to a research and commercialization strategy focused primarily on fast-follow and first-in-class drugs, supplemented by clinically needed biosimilars. It continuously innovates in areas such as pipeline construction, differentiation of platform technologies, and selection of indications, while also conducting basic research and its translation in areas of technological strength. According to the characteristics of its main business, the issuer has established business departments such as the Innovation Discovery Department (responsible for new project initiation and discovery of some early-stage projects), the Pharmacology Department (responsible for organizing and conducting pharmacological and efficacy studies in preclinical research), the New Drug R&D Department (responsible for pharmaceutical development work for some projects entering preclinical research), and the Clinical Medicine Department (responsible for organizing, managing, and implementing clinical trials for pipeline products) to carry out innovative research and development. Simultaneously, it leverages the technological platform advantages of different holding subsidiaries to independently or internally collaborate on drug discovery and development, thereby forming a complete new drug R&D and commercialization chain starting from basic research and translation.

Stock Details

1. Key Indicators

  • Total Shares(W): Unknown
  • Circulating A-Shares(W): Unknown
  • Earnings Per Share(RMB): Unknown
  • Net Assets Per Share(RMB): Unknown
  • Operating Revenue(W RMB): Unknown
  • Total Profit(W RMB): Unknown
  • **Net Profit Attributable to Parent(W RMB) **: Unknown
  • Net Profit Growth Rate(%): Unknown
  • Weighted Return on Equity(%): Unknown
  • Operating Cash Flow Per Share(RMB): Unknown
  • Undistributed Profit Per Share(RMB): Unknown
  • Capital Reserve Per Share(RMB): Unknown

2. Main Business

The main business covers:

  • Research and development of therapeutic biological products
  • Production of therapeutic biological products
  • Sales of therapeutic biological products

3. Company Basic Information

  • Company Name: Mabwell (Shanghai) Bioscience Co., Ltd.
  • Listing Date: 2022-01-18
  • Industry: Pharmaceutical Manufacturing
  • Address: Room 105, Building 2, No. 230 Cailun Road, China (Shanghai) Pilot Free Trade Zone
  • Website: https://www.mabwell.com/
  • Company Profile: On June 5, 2020, Ernst & Young Hua Ming LLP (Special General Partnership) issued the audit report EYHM(2020) No. 61474717_B01. As of April 30, 2020, the net assets of Mabwell Limited were RMB 2,271,029,500. On June 5, 2020, Fujian United Zhonghe Assets Appraisal, Land and Real Estate Appraisal Co., Ltd. issued the appraisal report United Zhonghe Ping Bao Zi (2020) No. 6140. As of the appraisal base date April 30, 2020, the book value of Mabwell Limited's net assets was RMB 2,271,029,500, and the appraisal result of the net assets was RMB 2,561,534,100. On June 20, 2020, Mabwell Limited held a shareholders' meeting and passed a resolution agreeing to convert Mabwell Limited in its entirety into a joint stock limited company, with all shareholders of Mabwell Limited acting as the promoters. All promoters converted the audited net assets of Mabwell Limited, RMB 2,271,029,500, into 299,700,000 shares at a ratio of 1:0.1320. The original shareholders of Mabwell Limited subscribed for the shares with the net assets corresponding to their respective shareholding ratios in Mabwell Limited. On June 20, 2020, all shareholders of Mabwell Limited signed the "Sponsorship Agreement for Mabwell (Shanghai) Bioscience Co., Ltd.", unanimously agreeing to convert Mabwell Limited in its entirety into a joint stock limited company. On June 21, 2020, Ernst & Young Hua Ming LLP (Special General Partnership) issued the capital verification report EYHM(2020) Yan Zi No. 61474717_B02, verifying that as of June 20, 2020, the company (pre-establishment) had received the registered capital of RMB 299,700,000 paid in by all promoters. On June 21, 2020, the company held its inaugural meeting and the first interim shareholders' meeting of 2020, reviewing and passing resolutions related to the conversion into a joint stock limited company, including the "Proposal on the Sponsors of the Joint Stock Company Subscribing for Shares of the Joint Stock Company by Converting the Net Assets of Mabwell (Shanghai) Bioscience Technology Co., Ltd.", agreeing to convert Mabwell Limited in its entirety into a joint stock limited company. On June 21, 2020, all promoters of the company jointly signed the "Articles of Association of Mabwell (Shanghai) Bioscience Co., Ltd.". On June 30, 2020, the Shanghai Municipal Administration for Market Regulation issued the "Business License" to the company. The Unified Social Credit Code is 91310115MA1K3Q5R7K.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
No Data Available - - - -

5. Concept Sectors

  • Biotechnology
  • Pharmaceuticals
  • Biological Products

Remarks

  • Data update date: Unknown
  • Data source: Public Market Information